Announcements Trials
Browse Landscape

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 693Neoplasms 610Prostatic Neoplasms 320Lung Neoplasms 309Colorectal Neoplasms 281Carcinoma, Non-Small-Cell Lung 253Pancreatic Neoplasms 178Carcinoma, Hepatocellular 169Stomach Neoplasms 143Multiple Myeloma 127Ovarian Neoplasms 121Melanoma 116Colonic Neoplasms 114Brain Neoplasms 108Hematologic Neoplasms 106Head and Neck Neoplasms 103Urinary Bladder Neoplasms 102Leukemia, Myeloid, Acute 100Esophageal Neoplasms 100Disease 97Liver Neoplasms 92Uterine Cervical Neoplasms 90Neoplasm Metastasis 89Lymphoma 86Rectal Neoplasms 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 82Endometrial Neoplasms 78Carcinoma, Renal Cell 74Leukemia 65Sarcoma 63

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Metastatic Hormone-sensitive Prostate Cancer × 1 year × Clear all
NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07031258 2025-06-22

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Nanfang Hospital, Southern Medical University

Not yet recruiting
50 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡